Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jason Alexander Efstathiou, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Brenneman RJ, Goddu SM, Andruska N, Roy A, Bosch WR, Fischer-Valuck B, Efstathiou JA, Gay HA, Michalski JM, Baumann BC. Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and CT/MRI Simulation for External Beam Radiation Therapy for Low and Intermediate-Risk Prostate Cancer. Pract Radiat Oncol. 2021 Oct 22. PMID: 34695615.
    Citations:    Fields:    
  2. Kamran SC, McClatchy DM, Pursley J, Trofimov AV, Remillard K, Saraf A, Ghosh A, Thabet A, Sutphin P, Miyamoto DT, Efstathiou JA. Characterization of an Iodinated Rectal Spacer for Prostate Photon and Proton Radiotherapy. Pract Radiat Oncol. 2021 Oct 04. PMID: 34619374.
    Citations:    Fields:    
  3. Chang E, Apolo AB, Bangs R, Chisolm S, Duddalwar V, Efstathiou JA, Goldberg KB, Hansel DE, Kamat AM, Kluetz PG, Lerner SP, Plimack E, Prowell T, Singh H, Suzman D, Yu EY, Zhang H, Beaver JA, Pazdur R, Weinstock C, Galsky MD. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2021 Sep 10. PMID: 34508246.
    Citations:    Fields:    
  4. Baumann BC, Sargos P, Efstathiou JA. Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain. Int J Radiat Oncol Biol Phys. 2021 09 01; 111(1):113-116. PMID: 34348106.
    Citations:    Fields:    Translation:Humans
  5. Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2021 Sep 01. PMID: 34481017.
    Citations:    Fields:    
  6. Seraphin TP, Joko-Fru WY, Hämmerl L, Griesel M, Mezger NCS, Feuchtner JC, Adoubi I, Egué MD, Okerosi N, Wabinga H, Hansen R, Vuma S, Lorenzoni C, Coulibaly B, Odzebe SW, Buziba NG, Aynalem A, Liu B, Medenwald D, Mikolajczyk RT, Efstathiou JA, Parkin DM, Jemal A, Kantelhardt EJ. Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: A population-based registry study. Cancer. 2021 Nov 15; 127(22):4221-4232. PMID: 34328216.
    Citations:    Fields:    
  7. Moteabbed M, Harisinghani M, Paganetti H, Trofimov A, Lu HM, Efstathiou JA. Proton vs. photon radiotherapy for MR-guided dose escalation of intraprostatic lesions. Acta Oncol. 2021 Oct; 60(10):1283-1290. PMID: 34282708.
    Citations:    Fields:    Translation:Humans
  8. Efstathiou JA, Kamran SC, Spratt DE. Protons Versus Photons for Prostate Cancer: An Answer That Is Long Overdue and Coming. Int J Radiat Oncol Biol Phys. 2021 07 15; 110(4):1098-1100. PMID: 34171235.
    Citations:    Fields:    Translation:Humans
  9. Kumar A, Cherry DR, Courtney PT, Nalawade V, Kotha N, Riviere PJ, Efstathiou J, McKay RR, Karim Kader A, Rose BS, Stewart TF. Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans. Eur Urol Open Sci. 2021 Aug; 30:1-10. PMID: 34337540.
    Citations:    
  10. Rais-Bahrami S, Efstathiou JA, Turnbull CM, Camper SB, Kenwright A, Schuster DM, Scarsbrook AF. 18F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 2021 May 19. PMID: 34012062.
    Citations: 1     Fields:    
  11. Campbell SR, Tom MC, Agrawal S, Efstathiou JA, Michalski JM, Abramowitz MC, Pollack A, Spratt DE, Hearn JWD, Stephans KL, Gao T, Li J, Tendulkar RD. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. Eur Urol Oncol. 2021 May 17. PMID: 34016556.
    Citations:    Fields:    
  12. Kamran SC, Efstathiou JA. Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. Front Oncol. 2021; 11:675311. PMID: 34026653.
    Citations: 1     
  13. Solanki AA, Venkatesulu BP, Efstathiou JA. Will the Use of Biomarkers Improve Bladder Cancer Radiotherapy Delivery? Clin Oncol (R Coll Radiol). 2021 06; 33(6):e264-e273. PMID: 33867226.
    Citations:    Fields:    
  14. Konieczkowski DJ, Efstathiou JA, Mouw KW. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. Hematol Oncol Clin North Am. 2021 Jun; 35(3):567-584. PMID: 33958151.
    Citations:    Fields:    
  15. Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552. PMID: 33570548.
    Citations: 2     Fields:    
  16. Royce TJ, Liu Y, Milowsky MI, Efstathiou JA, Jani AB, Fischer-Valuck B, Patel SA. Trimodality Therapy With or Without Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2021 08; 19(4):362-368. PMID: 33839040.
    Citations:    Fields:    Translation:Humans
  17. Pieretti A, Krasnow R, Drumm M, Gusev A, Dahl DM, McGovern F, Blute ML, Shipley WU, Efstathiou JA, Feldman AS, Wszolek MF. Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. J Urol. 2021 Jul; 206(1):29-36. PMID: 33617327.
    Citations:    Fields:    Translation:Humans
  18. Dykstra M, Malone B, Lekuntwane O, Efstathiou J, Letsatsi V, Elmore S, Castro C, Tapela N, Dryden-Peterson S. Impact of Community-Based Clinical Breast Examinations in Botswana. JCO Glob Oncol. 2021 01; 7:17-26. PMID: 33405960.
    Citations: 1     Translation:HumansPHPublic Health
  19. Black PC, Efstathiou J. Setting the stage for bladder preservation. Urol Oncol. 2021 04; 39(4):209-212. PMID: 33008753.
    Citations: 1     Fields:    
  20. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):174-185. PMID: 32861817.
    Citations: 3     Fields:    Translation:Humans
  21. Cuenca AG, Rosales I, Lee RJ, Wu CL, Colvin R, Feldman AS, Efstathiou JA, Tolkoff-Rubin N, Elias N. Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. Transplant Proc. 2020 Nov; 52(9):2720-2725. PMID: 32741665.
    Citations:    Fields:    Translation:HumansCells
  22. Fischer-Valuck BW, Michalski JM, Harton JG, Birtle A, Christodouleas JP, Efstathiou JA, Arora VK, Kim EH, Knoche EM, Pachynski RK, Picus J, Rao YJ, Reimers M, Roth BJ, Sargos P, Smith ZL, Zaghloul MS, Gay HA, Patel SA, Baumann BC. Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. Clin Genitourin Cancer. 2021 02; 19(1):41-46.e1. PMID: 33187904.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  23. Miller LE, Efstathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 06 01; 3(6):e208221. PMID: 32585020.
    Citations: 6     Fields:    Translation:Humans
  24. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M, Spratt DE. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 09 10; 38(26):3024-3031. PMID: 32396488.
    Citations: 3     Fields:    Translation:Humans
  25. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 05 01; 6(5):735-743. PMID: 32215583.
    Citations: 5     Fields:    Translation:Humans
  26. de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020 08; 3(4):420-423. PMID: 32205136.
    Citations: 3     Fields:    Translation:HumansCells
  27. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 03; 18(3):329-354. PMID: 32135513.
    Citations: 56     Fields:    Translation:Humans
  28. Solanki AA, Efstathiou JA. EDITORIAL COMMENT. Urology. 2019 11; 133:171-172. PMID: 31706416.
    Citations:    Fields:    Translation:Humans
  29. Leow JJ, Catto JWF, Efstathiou JA, Gore JL, Hussein AA, Shariat SF, Smith AB, Weizer AZ, Wirth M, Witjes JA, Trinh QD. Quality Indicators for Bladder Cancer Services: A Collaborative Review. Eur Urol. 2020 07; 78(1):43-59. PMID: 31563501.
    Citations: 2     Fields:    Translation:Humans
  30. Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Reply by Authors. J Urol. 2019 10; 202(4):821-822. PMID: 31163004.
    Citations:    Fields:    Translation:Humans
  31. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020 01; 77(1):38-52. PMID: 31493960.
    Citations: 94     Fields:    Translation:Humans
  32. Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948. PMID: 31390585.
    Citations:    Fields:    Translation:Humans
  33. Nogueira LM, Sahar L, Efstathiou JA, Jemal A, Yabroff KR. Association Between Declared Hurricane Disasters and Survival of Patients With Lung Cancer Undergoing Radiation Treatment. JAMA. 2019 07 16; 322(3):269-271. PMID: 31310288.
    Citations: 6     Fields:    Translation:Humans
  34. Fish M, Parkes J, Dharsee N, Dryden-Peterson S, Efstathiou J, Schnipper L, Chabner BA, Parikh AR. POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. Oncologist. 2019 12; 24(12):1557-1561. PMID: 31182656.
    Citations: 4     Fields:    Translation:Humans
  35. Iyer HS, Kohler RE, Ramogola-Masire D, Brown C, Molebatsi K, Grover S, Kablay I, Bvochora-Nsingo M, Efstathiou JA, Lockman S, Tapela N, Dryden-Peterson SL. Explaining disparities in oncology health systems delays and stage at diagnosis between men and women in Botswana: A cohort study. PLoS One. 2019; 14(6):e0218094. PMID: 31170274.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  36. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol. 2019 09; 37(9):599-610. PMID: 31060795.
    Citations: 5     Fields:    Translation:Humans
  37. Kamran SC, Light JO, Efstathiou JA. Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. Prostate Cancer Prostatic Dis. 2019 12; 22(4):509-521. PMID: 30967625.
    Citations: 3     Fields:    Translation:Humans
  38. Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 07 01; 25(13):3908-3920. PMID: 30952638.
    Citations: 15     Fields:    Translation:HumansCells
  39. Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol. 2019 04; 201(4):721-727. PMID: 30664083.
    Citations: 4     Fields:    Translation:Humans
  40. Mouw KW, Miyamoto DT, Efstathiou JA. Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer. Eur Urol. 2019 07; 76(1):71-72. PMID: 30910345.
    Citations: 1     Fields:    Translation:Humans
  41. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. J Urol. 2019 03; 201(3):528-534. PMID: 30759696.
    Citations: 14     Fields:    Translation:Humans
  42. Royce TJ, Efstathiou JA. Editorial comment. Urology. 2019 Feb; 124:189-190. PMID: 30784711.
    Citations:    Fields:    Translation:Humans
  43. Efstathiou JA, Choudhury A, Kiltie AE. Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Surg. 2019 02 01; 154(2):184-185. PMID: 30477011.
    Citations:    Fields:    Translation:Humans
  44. Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol. 2019 07; 76(1):59-68. PMID: 30712971.
    Citations: 37     Fields:    Translation:HumansCells
  45. Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019 Jan; 37(1):61-83. PMID: 30684034.
    Citations: 11     Fields:    Translation:Humans
  46. Meng W, Efstathiou J, Singh R, McElroy J, Volinia S, Cui R, Ibrahim A, Johnson B, Gupta N, Mehta S, Wang H, Miller E, Nguyen P, Fleming J, Wu CL, Haque SJ, Shipley W, Chakravarti A. MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. Int J Radiat Oncol Biol Phys. 2019 05 01; 104(1):197-206. PMID: 30583038.
    Citations: 5     Fields:    Translation:HumansCells
  47. Yerramilli D, Moghanaki DM, Efstathiou JA. Safeguarding Autonomy of Patients With Bladder Cancer. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):81-83. PMID: 30563669.
    Citations:    Fields:    Translation:Humans
  48. Royce TJ, Efstathiou JA. Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. Urol Oncol. 2019 09; 37(9):628-636. PMID: 30527342.
    Citations: 3     Fields:    Translation:Humans
  49. Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol. 2018 12; 19(12):e683-e695. PMID: 30507435.
    Citations: 24     Fields:    Translation:HumansAnimals
  50. Efstathiou JA, Drumm MR, Paly JP, Lawton DM, O'Neill RM, Niemierko A, Leffert LR, Loeffler JS, Shih HA. Long-term impact of a faculty mentoring program in academic medicine. PLoS One. 2018; 13(11):e0207634. PMID: 30496199.
    Citations: 6     Fields:    Translation:Humans
  51. Solanki AA, Bossi A, Efstathiou JA, Lock D, Mondini M, Ramapriyan R, Welsh J, Kang J. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. Eur Urol Oncol. 2019 02; 2(1):79-87. PMID: 30929848.
    Citations: 6     Fields:    Translation:Humans
  52. Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2019 01 01; 37(1):44-51. PMID: 30433852.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  53. Hwang WL, Niemierko A, Efstathiou JA. Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy-Reply. JAMA Oncol. 2018 11 01; 4(11):1620-1621. PMID: 30422248.
    Citations:    Fields:    Translation:Humans
  54. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):354-360. PMID: 30322661.
    Citations: 40     Fields:    Translation:Humans
  55. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol. 2018 Oct 11; JCO1801097. PMID: 30307776.
    Citations: 32     Fields:    
  56. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Urol. 2018 Oct 09. PMID: 30316897.
    Citations: 4     Fields:    
  57. Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, Efstathiou JA. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2019 Feb; 17(1):23-31.e3. PMID: 30482661.
    Citations: 6     Fields:    Translation:Humans
  58. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 09; 16(9):1041-1053. PMID: 30181416.
    Citations: 42     Fields:    Translation:Humans
  59. Sargos P, Baumann BC, Eapen L, Christodouleas J, Bahl A, Murthy V, Efstathiou J, Fonteyne V, Ballas L, Zaghloul M, Roubaud G, Orré M, Larré S. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev. 2018 Nov; 70:88-97. PMID: 30125800.
    Citations: 7     Fields:    Translation:Humans
  60. Moteabbed M, Trofimov A, Khan FH, Wang Y, Sharp GC, Zietman AL, Efstathiou JA, Lu HM. Impact of interfractional motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer. Med Phys. 2018 Jul 14. PMID: 30007067.
    Citations: 3     Fields:    
  61. Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):287-295. PMID: 29913254.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  62. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 05 10; 4(5):e175230. PMID: 29372236.
    Citations: 20     Fields:    Translation:Humans
  63. Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 09; 74(3):294-306. PMID: 29755006.
    Citations: 45     Fields:    Translation:Humans
  64. Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1188-1193. PMID: 29891203.
    Citations: 2     Fields:    Translation:Humans
  65. Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene. 2018 05; 37(21):2793-2805. PMID: 29511347.
    Citations: 12     Fields:    Translation:HumansCells
  66. Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S, Haber DA. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov. 2018 03; 8(3):288-303. PMID: 29301747.
    Citations: 40     Fields:    Translation:HumansCellsCTClinical Trials
  67. Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018 06; 16(3):213-218. PMID: 29289519.
    Citations: 1     Fields:    Translation:Humans
  68. Wo JY, Drapek LC, Niemierko A, Silvia B, Noé BN, Russo AL, Miyamoto DT, Hong TS, Efstathiou JA, Zietman AL, Dizon DS. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Pract Radiat Oncol. 2018 May - Jun; 8(3):206-212. PMID: 29426693.
    Citations:    Fields:    Translation:Humans
  69. Royce TJ, Lin CC, Gray PJ, Shipley WU, Jemal A, Efstathiou JA. Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base. Urol Oncol. 2018 02; 36(2):78.e1-78.e12. PMID: 29162314.
    Citations: 7     Fields:    Translation:Humans
  70. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2018 07; 74(1):99-106. PMID: 29128208.
    Citations: 6     Fields:    Translation:Humans
  71. Müller BS, Shih HA, Efstathiou JA, Bortfeld T, Craft D. Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors. Radiat Oncol. 2017 Nov 06; 12(1):168. PMID: 29110689.
    Citations: 8     Fields:    Translation:Humans
  72. Gakis G, Schubert T, Morgan TM, Daneshmand S, Keegan KA, Mischinger J, Clayman RH, Brisuda A, Ali-El-Dein B, Galland S, Gregg J, Balci M, Olugbade K, Rink M, Fritsche HM, Burger M, Babjuk M, Stenzl A, Thalmann GN, Kübler H, Efstathiou JA. The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. Urol Oncol. 2018 01; 36(1):10.e7-10.e14. PMID: 29055518.
    Citations: 4     Fields:    Translation:Humans
  73. Ahamad A, Martinez A, Salenius S, Ross R, Efstathiou J, Fernandez E. Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers. Urol Oncol. 2018 01; 36(1):9.e19-9.e25. PMID: 28993060.
    Citations:    Fields:    Translation:Humans
  74. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267. PMID: 28982750.
    Citations: 76     Fields:    Translation:Humans
  75. Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou JA. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol. 2018 02; 199(2):407-415. PMID: 28870862.
    Citations: 9     Fields:    Translation:Humans
  76. Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer. 2017 Aug 03. PMID: 28864223.
    Citations: 2     Fields:    
  77. Giacalone NJ, Niemierko A, Shipley WU, Efstathiou JA. Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation. Eur Urol. 2017 09; 72(3):e64-e65. PMID: 28642020.
    Citations: 1     Fields:    Translation:Humans
  78. Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL. Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Med. 2017 Jul; 6(7):1827-1836. PMID: 28560840.
    Citations: 11     Fields:    Translation:Humans
  79. Xiang HF, Lu HM, Efstathiou JA, Zietman AL, De Armas R, Harris K, Bloch BN, Qureshi MM, Keohan S, Hirsch AE. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys. 2017 05; 18(3):37-43. PMID: 28407345.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
  80. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. J Clin Oncol. 2017 May 20; 35(15):1737-1743. PMID: 28346805.
    Citations: 26     Fields:    Translation:Humans
  81. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations. Phys Med Biol. 2017 03 07; 62(5):1644-1660. PMID: 28166057.
    Citations: 6     Fields:    Translation:Humans
  82. Baumann BC, Sargos P, Eapen LJ, Efstathiou JA, Choudhury A, Bahl A, Murthy V, Ballas LK, Fonteyne V, Richaud PM, Zaghloul MS, Christodouleas JP. The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer. 2017 Jan 27; 3(1):19-30. PMID: 28149931.
    Citations: 6     
  83. Kamran SC, Harshman LC, Bhagwat MS, Muralidhar V, Nguyen PL, Martin NE, La Follette S, Faso S, Viswanathan AN, Efstathiou JA, Beard CJ. Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):140-147. PMID: 28740925.
    Citations: 3     
  84. Underwood TS, Voog JC, Moteabbed M, Tang S, Soffen E, Cahlon O, Lu HM, Zietman AL, Efstathiou JA, Paganetti H. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol. 2017 Apr; 56(4):575-581. PMID: 28075206.
    Citations: 3     Fields:    Translation:Humans
  85. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960. PMID: 28081860.
    Citations: 58     Fields:    Translation:Humans
  86. van Soest RJ, Efstathiou JA, Sternberg CN, Tombal B. The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. Eur Urol Focus. 2016 Dec; 2(5):480-487. PMID: 28723513.
    Citations: 5     Fields:    
  87. Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2017 07; 72(1):54-60. PMID: 28040351.
    Citations: 11     Fields:    Translation:Humans
  88. Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461. PMID: 28011046.
    Citations: 7     Fields:    Translation:Humans
  89. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, Grover S, Chiyapo S, Ramogola-Masire D, Kebabonye-Pusoentsi M, Clayman R, Mapes AC, Tapela N, Asmelash A, Medhin H, Viswanathan AN, Russell AH, Lin LL, Kayembe MKA, Mmalane M, Randall TC, Chabner B, Lockman S. HIV Infection and Survival Among Women With Cervical Cancer. J Clin Oncol. 2016 11 01; 34(31):3749-3757. PMID: 27573661.
    Citations: 39     Fields:    Translation:Humans
  90. Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3. PMID: 28462857.
    Citations:    Fields:    Translation:Humans
  91. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3648-3654. PMID: 27528718.
    Citations: 72     Fields:    
  92. Buscariollo DL, Drumm M, Niemierko A, Clayman RH, Galland-Girodet S, Rodin D, Feldman AS, M Dahl D, McGovern FJ, F Olumi A, Eidelman A, Shipley WU, Zietman AL, Efstathiou JA. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e125-e133. PMID: 28274403.
    Citations: 5     Fields:    Translation:Humans
  93. Efstathiou JA. Introduction. Semin Radiat Oncol. 2017 01; 27(1):1-2. PMID: 27986206.
    Citations:    Fields:    Translation:HumansPHPublic Health
  94. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224. PMID: 27697976.
    Citations: 36     Fields:    Translation:Humans
  95. Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, Orré M, Efstathiou JA, Shariat S, Larré S, Richaud P, Christodouleas JP. Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider? Transl Androl Urol. 2016 Oct; 5(5):702-710. PMID: 27785427.
    Citations: 6     
  96. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053. PMID: 27745980.
    Citations: 12     Fields:    Translation:Humans
  97. Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol. 2017 05; 71(5):729-737. PMID: 27597241.
    Citations: 28     Fields:    Translation:Humans
  98. Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1028-1036. PMID: 27727064.
    Citations: 25     Fields:    Translation:Humans
  99. Roberts HJ, Zietman AL, Efstathiou JA. Painting Dose: The ART of Radiation. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):722-728. PMID: 27788945.
    Citations:    Fields:    Translation:Humans
  100. Gakis G, Efstathiou JA, Daneshmand S, Keegan KA, Clayman RH, Hrbacek J, Ali-El-Dein B, Zaid HB, Schubert T, Mischinger J, Todenhöfer T, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Morgan TM. Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. Urol Int. 2016; 97(2):134-41. PMID: 27462702.
    Citations: 1     Fields:    Translation:Humans
  101. Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urol Oncol. 2017 02; 35(2):59-68. PMID: 27395453.
    Citations: 12     Fields:    Translation:Humans
  102. Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut MH, Hamstra DA, Roof KS, Jeffrey Lee R, Gore EM, Sandler HM, Shipley WU. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016 10; 34(10):430.e1-7. PMID: 27381895.
    Citations: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  103. Benedict SH, Hoffman K, Martel MK, Abernethy AP, Asher AL, Capala J, Chen RC, Chera B, Couch J, Deye J, Efstathiou JA, Ford E, Fraass BA, Gabriel PE, Huser V, Kavanagh BD, Khuntia D, Marks LB, Mayo C, McNutt T, Miller RS, Moore KL, Prior F, Roelofs E, Rosenstein BS, Sloan J, Theriault A, Vikram B. Overview of the American Society for Radiation Oncology-National Institutes of Health-American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. Int J Radiat Oncol Biol Phys. 2016 07 01; 95(3):873-879. PMID: 27302503.
    Citations: 11     Fields:    Translation:Humans
  104. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810. PMID: 27345655.
    Citations: 305     Fields:    Translation:Humans
  105. Makufa R, Bvochora-Nsingo M, Karumekayi T, Schneider RJ, Efstathiou JA, Dryden-Peterson S, Odom A, Shulman A, Pipman Y, Gierga DP. SU-F-P-09: A Global Medical Physics Collaboration for Implementation of Modern Radiotherapy in Botswana. Med Phys. 2016 Jun; 43(6):3359-3360. PMID: 28047638.
    Citations:    
  106. Moteabbed M, Trofimov A, Sharp G, Wang Y, Zietman A, Efstathiou J, Lu H. SU-G-JeP4-09: Impact of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy for Prostate Cancer. Med Phys. 2016 Jun; 43(6):3683. PMID: 28046335.
    Citations:    
  107. Paly JJ, Lin CC, Gray PJ, Hallemeier CL, Beard C, Sineshaw H, Jemal A, Efstathiou JA. Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e249-e258. PMID: 27345128.
    Citations: 4     Fields:    Translation:Humans
  108. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):78-86. PMID: 27511849.
    Citations: 13     Fields:    Translation:Humans
  109. Hedgire S, Tonyushkin A, Kilcoyne A, Efstathiou JA, Hahn PF, Harisinghani M. Quantitative study of prostate cancer using three dimensional fiber tractography. World J Radiol. 2016 Apr 28; 8(4):397-402. PMID: 27158426.
    Citations: 2     
  110. Shah A, Ricci KI, Efstathiou JA. Beyond a moonshot: insurance coverage for proton therapy. Lancet Oncol. 2016 05; 17(5):559-61. PMID: 27301029.
    Citations: 5     Fields:    Translation:Humans
  111. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138.
    Citations: 7